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Objectives: To assess disease-free survival (DFS) in head and neck squamous cell carcinoma (HNSCC)
treated with (chemo)radiotherapy ([C]RT).
Methods: Pretreatment MR-images of 78 patients were retrospectively studied. Apparent diffu-
sion coefﬁcients (ADC) were calculated with two sets of two b-values: 0–750 s/mm2 (ADC750) and
0–1000 s/mm2 (ADC1000). One observer assessed tumor volume on T1-WI. Two independent observers
assessed ADC-values of primary tumor and largest lymph node in two sessions (i.e. without and with
including CE-T1WI in image analysis). Interobserver and intersession agreementwere assessedwith intr-
aclass correlation coefﬁcients (ICC) separately for ADC750 and ADC1000. Lesion volumes and ADC-values
were related to DFS using Cox regression analysis.
Results: Median follow-up was 18 months. Interobserver ICC was better without than with CE-T1WI
(primary tumor: 0.92 and 0.75–0.83, respectively; lymph node: 0.81–0.83 and 0.61–0.64, respectively).
Intersession ICC ranged from 0.84 to 0.89. With CE-T1WI, mean ADC-values of primary tumor and lymph
node were higher at both b-values than without CE-T1WI (P<0.001). Tumor volume (sensitivity: 73%;
speciﬁcity: 57%) and lymph node ADC1000 (sensitivity: 71–79%; speciﬁcity: 77–79%) were independent
signiﬁcant predictors of DFS without and with including CE-T1WI (P<0.05).
Conclusions: Pretreatment primary tumor volume and lymph node ADC1000 were signiﬁcant independent
predictors of DFS inHNSCC treatedwith (C)RT. DFS could be predicted fromADC-values acquiredwithout
and with including CE-T1WI in image analysis. The inclusion of CE-T1WI did not result in signiﬁcant
improvements in the predictive value of DWI. DWI without including CE-T1WI was highly reproducible.
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Head and neck cancer accounts for approximately 3% of all
malignancies [1]. Treatment selection is based on the best tradeoff
between cure rate andquality of life and consists of (a combination)
of surgery, chemotherapy and radiotherapy depending on disease
stage [2].
Withbetter treatment selection, patientswith ahighprobability
of an unfavorable treatment outcome after (chemo)radiotherapy
([C]RT) could undergo primary surgical treatment. The same
applies when treatment response to (C)RT can be monitored in an
early stage; then (C)RT might be terminated prematurely. After a
full (C)RT treatment, salvage surgery with curative intent is still
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ossible to perform, however this is not preferred because of a
igher risk of complications like impaired wound healing. More-
ver, salvage treatment is not always possible because of extension
f the residual or recurrent tumor outside its original location.
herefore a minority of patients (21–31%) receives salvage surgery
fter local failure [3–5].
Diffusion-weighted imaging (DWI) is anemergingmagnetic res-
nance imaging (MRI) technique in response prediction in HNSCC
atients treated with (C)RT [6].
DWI is based on differences in water mobility in different tis-
ues which can be quantiﬁed into an apparent diffusion coefﬁcient
ADC) [7]. The extent of diffusion weighting depends on the tim-
ng and the strength of the gradient and is expressed as a b-value.
n order to reconstruct an ADC at least two different b-values are
eeded, typically a low (e.g. <150 s/mm2) and a high b-value (e.g.
700 s/mm2) are used. In hypercellular tissue (e.g. tumor tissue)
ith a small amount of extracellular space diffusion is restricted,
hich gives a low ADC-value. In contrary, in hypocellular tissue
here diffusion in the extracellular space is facilitated, ADC-values
re high. Necrosis and inﬂammation generally meet these criteria
8,9]. There is still no consensus on the optimal combination of b-
alues, though a combination of b=0 s/mm2 and b=1000 s/mm2 is
ommonly used [9–15].
Diffusion-weighted imaging has shown potential in the predic-
ion of prognosis in patients with head and neck squamous cell
arcinoma (HNSCC) treated with (C)RT and to monitor therapy in
very early stage. Higher pretreatment ADC values are associated
ith adverse prognosis [8,12,13,16]. Furthermore DWI has shown
otential to detect central necrosis and (subcentimeter) metastatic
ymph nodes [9,15].
Contrast-enhanced imaging is often used to exclude necrosis,
hich allows that theADC-value only of the solid part of lesions can
e determined [9,15]. To our knowledge there has not been a study
hat assessed the clinical relevance of using contrast-enhanced
maging for excluding necrosis on DWI. Hatakenaka et al. [10] did
uggest that pretreatmentADCwould be superior to CE-MRI to pre-
ict local failure. Since DWI and contrast-enhanced imaging are
ased on different properties, both techniques may be synergistic
n predicting the outcome of treatment.
Thepurposeof this studywas to assess thepredictionof disease-
ree survival (DFS) and interobserver agreement of DWI without
nd with including contrast-enhanced T1-weighted imaging (CE-
1WI) in image analysis of HNSCC treated with (C)RT.
. Methods and materials
.1. Study population
This retrospective study was approved by the local ethics com-
ittee. The requirement for informed consent was waived.
Inclusion criteria were histologically proven HNSCC treated
ith (C)RT in the oral cavity, oropharynx, hypopharynx or larynx
nd turbo spin-echo (TSE)-DWI of adequate diagnostic quality for
he primary tumor or the lymphnode on at least one b-value image.
xclusion criteriawere previousmalignancies in the head and neck
rea and distant metastases at the start of therapy. All patients
ere clinically assessedbyaheadandneck surgeonwhoperformed
physical examination and endoscopic evaluation of the primary
umor. N-stage was assessed using ultrasound-guided ﬁne-needle
spiration cytology. A total of 111 consecutive patients received
re-treatmentDWI and (C)RT of the head andneck betweenAugust
009 and December 2011. To allow for optimally comparable data
e selected the largest patient group which was scanned on the
ame MR-system, therefore 18 patients were excluded due to the
se of another MR-system. One patient was excluded because noRadiology 84 (2015) 108–116 109
CE-T1WI was acquired. Fourteen patients were excluded because
neither the primary tumor nor the largest lymph node was visible
on DWI due to small tumor size (n=8) or poor image quality (n=4).
Finally, the study consisted of 78 patients. In all 78 patients b1000-
imagese were acquired. In 64 of these patients b750-images were
also acquired. See Fig. S1 in the Electronic Supplementary Material
for a detailed ﬂow-chart of patient inclusion.
Supplementary Fig. S1 related to this article can be found, in the
online version, at http://dx.doi.org/10.1016/j.ejrad.2014.10.015.
Radiotherapy was delivered to the primary tumor and affected
lymph nodes to a total dose of 70Gy in 35 fractions of 2Gy in 70
patients. Three patients received a total dose of 69Gy in 30 frac-
tions of 2.3Gy. All these 73 patients received an elective dose to
the lymph nodes at risk for microscopic tumor. In 4 patients a total
dose of 52Gy was delivered in 16 fractions of 3.25Gy. One patient
received 60Gy in 25 fractions of 2.4Gy. In the these last 5 patients,
no elective dose to the lymph node regions was given. Thirty-
eight patients received additional chemotherapy (i.e. 100mg/m2
cisplatin in theﬁrst, fourthandseventhweekafter the startof radio-
therapy (n=24) or 400mg/m2 cetuximab oneweek before the start
of radiotherapy followed by 250mg/m2 every week during radio-
therapy (n=14)). Patient, tumor and treatment characteristics are
summarized in Table S1 in the Electronic Supplementary Material.
Median time between MRI examinations and the start of treatment
was 25 days (range, 7–63 days).
Supplementary Table S1 related to this article can be found,
in the online version, at http://dx.doi.org/10.1016/j.ejrad.2014.
10.015.
Follow-upconsistedof clinical assessmentevery6–8weeksdur-
ing the ﬁrst year, every 2–3 months during the second year and
every 3–4 months in the third year. Additional imaging and diag-
nostic procedures were performed in case of clinical suspicion of
recurrent disease, residual disease or distant metastases. Positive
biopsy or locoregional disease progression within six months after
the end of treatment was considered to be residual disease; after
six months it was considered to be a locoregional recurrence.
2.2. MR imaging
Imaging was performed on a 1.5 T system (Signa HDxt; GE
Healthcare, Milwaukee, WI, United States), using a standard head
and neck coil with 29 elements. For all sequences the FOV was
250mm. DWI was acquired using two PROPELLER sequences with
two sets of two b-values: b=0 and 750 s/mm2 and b=0 and
1000 s/mm2, respectively. ADC-maps were calculated by using
two sets of b-values: b=0 and 750 s/mm2 (ADC750) and b=0
and 1000 s/mm2 (ADC1000). After the administration of 0.4ml/kg
gadoteric acid (Dotarem; Guerbet, Roissy, France) in 72 patients
and 0.2ml/kg gadobutrol (Gadovist; Bayer Schering AG, Berlin,
Germany) in 6 patients, CE-T1WI without fat saturation was
acquired. An overview of our imaging protocol is provided in Table
S2 in the Electronic Supplementary Material.
Supplementary Table S2 related to this article can be found,
in the online version, at http://dx.doi.org/10.1016/j.ejrad.2014.
10.015.
Because of differences in resolution and to correct for patient
movement, CE-T1WI and DWI were co-registered using the lin-
ear registration software tool FLIRT from the FSL package (FMRIB
Center, Oxford, United Kingdom).
2.3. Image analysisImages were evaluated with Centricity Radiology RA 600
(version 6.1, GE Healthcare, Milwaukee, WI, USA). Volume of
the primary tumor and largest lymph node were assessed on
T1-weighted images by one reader (JCA) by drawing manual ROIs
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n each slice containing the lesion. The same reader also assessed
he short axis diameter of the largest lymph node [17].
Image analysis without and with including CE-T1WI in image
nalysiswas done in two sessions by two radiologists (JCA andPGR)
ith 21 and 6 years of experience in head and neck radiology. In
oth sessions observers had access to conventional MR-sequences
or anatomical correlation, and patient information regarding age,
ender, global tumor location (i.e. oral cavity, oropharynx, larynx
nd hypopharynx) and TNM-stage, but were blinded to treatment
utcome and the results of the other observer. In the ﬁrst session
bservers had access to all diffusion sequences (i.e. b0, b750, b1000
nd corresponding ADC-maps) but not to the CE-T1WI. Free-hand
egions of interest (ROIs)were drawnon the high b-value images to
elineate the solid parts of the tumor and largest lymphnodeon the
lide that contained the core of the lesion, avoiding areas of necro-
is. Solid parts were characterized by a high signal intensity on the
igh b-value images and low signal intensity on the ADC-map. ROIs
ere copied from the high b-value images to the ADC-map. Mean
DC-value and ROI volume were recorded. Image quality of DWI
as assessed separately for the primary tumor and largest lymph
ode using a ﬁve-point Likert scale: 1 = inadequate; 2 =moderate;
= fair; 4 = good; 5= excellent.
In the second session observers had access to CE-T1WIweighted
mages, b0 images and ADC-maps, but not to high b-value images.
n CE-T1WI single slice free-hand ROIs were placed on the
ontrast-enhancingpart of the tumorand largest lymphnode, again
reas of necrosis were avoided. The ROI was ﬁrst copied to the
0-image to verify the anatomical position and subsequently to the
DC-map. Again mean ADC-value and ROI volume were recorded.
o minimize recall bias, the second session was at least four weeks
fter the ﬁrst. To ensure that the same lesionswere assessed in both
essions, observers had access to the slice position of the ROI in the
rst session.
.4. Statistical analysis
Statistical analyses were performed using SPSS (version 20.0;
hicago, IL, USA).Wilcoxon signed rank testswere used to compare
he image quality of both b-values for both observers separately
nd to compare ROI volumes acquired without and with including
E-T1WI in image analysis. Interobserver agreement and inters-
ssion agreement (i.e. between ADC-values acquired without and
ith including CE-T1WI in image analysis) were assessed by calcu-
ating the two-way mixed model intraclass correlation coefﬁcient
ICC) [18]. ICCs can be interpreted according to Nunnally [19]:
echniques with an ICC>0.80 are reliable for basic research, to be
linically applicable ICCs >0.90 are necessary.
Mean ADC-values of both observers were used for subsequent
nalyses. We compared ADC-values derived without and with
ncluding CE-T1WI in image analysis by using paired sample t-tests
nd Bland–Altman plots. Paired sample t-tests were also used to
ompare ADC750 with ADC1000.
DFS was assessed for various predictors using univariable Cox
egression analysis. Signiﬁcant predictors were tested further with
ultivariable Cox regression analysis. ROC analyseswas performed
o determine the optimal cut-off value with the highest Youden
ndex for lesion volume and ADC-values in predicting DFS. This
ptimal cut-off was used to create Kaplan–Meier curves of these
ontinuous variables.
. Results.1. Treatment outcome
Median follow-upwas18months (interquartile rang (IQR), 9–25
onths). Five patients were censored because of a second primaryRadiology 84 (2015) 108–116
tumor. One patient died due to euthanasia. This patient was cen-
sored because we did not consider this to be death due to disease
progression. Sixty-nine percent (54/78) of the patients remained
disease-free during follow-up. During follow-up, biopsies were
positive for malignancy in 23% (18/78) of the patients. Five patients
had residual disease, eight developed a locoregional recurrence and
ﬁve patients were diagnosed with distant metastasis.
3.2. Image analysis
In 88% (56/64) of the patients the primary tumor was visible on
b750-images, on b1000-images in 79% (62/78). Lymph nodes could
be evaluated on b750-images in 96% (49/51) of the patients and
b1000-images in 93% (57/61) (Table 1) (Fig. S1).
According to both observers the primary tumor (P<0.05) and
largest lymph node (P>0.05) were better depicted on the b750
images than the b1000 images (Table 1). Median primary tumor
volume was 7.3 cm3 (IQR, 2.7–14.6 cm3) with median lymph node
volume being 1.3 cm3 (IQR, 0.5–4.2 cm3) and median minimal axial
diameter of the largest nodebeing8.2mm(IQR, 5.5–15.4mm). Rep-
resentative images are shown in Fig. 1.
3.3. Interobserver agreement
Without including CE-T1WI in image analysis ICC for ADC-
values of the primary tumor was 0.92 for both b-values. For the
largest lymph node ICC was 0.75 for the ADC750 and 0.83 for the
ADC1000. Including CE-T1WI in image analysis resulted in lower
ICCs being 0.81 and 0.83 for the primary tumor for the ADC750 and
ADC1000 respectively. In lymph nodes these values were also lower
being 0.64 for ADC750 and 0.61 for ADC1000 (Table 1).
3.4. Comparison between ADC-values and ROI volumes without
and with including CE-T1WI in image analysis
Regardless of including CE-T1WI in image analysis ADC750 was
higher than ADC1000 in both primary tumor and lymph node
(P<0.001). The Bland–Altman plots are provided in Fig. 2. With
inclusion of CE-T1WI, mean ADC-values of primary tumor and
lymph node were higher at both b-values than without CE-T1WI
(P<0.001). Also ROIs were larger when including CE-T1WI. This
difference in ROI volume was signiﬁcant (P=0.002), except for
the ADC750 of the primary tumor (P>0.05). Biases (i.e. mean
difference without and with including CE-T1WI) ranged from
−0.14×10−3 mm2/s to −0.18×10−3 mm2/s with ICC ranging from
0.84 to 0.89 (Table 2).
3.5. Survival analysis
Results of ROC analysis are shown in Table 3. Area under the
curve ranged from 0.54 to 0.82.
Without including CE-T1WI in image analysis, signiﬁcant pro-
gnostic factors in univariable Cox regression of DFS were large
primary tumor volume on T1 (P=0.001), and a high lymph
node ADC1000 (P=0.001). Primary tumor ADC750, primary tumor
ADC1000, lymph node volume on T1, minimal axial diameter on T1
and lymph node ADC750 were not signiﬁcant parameters (P>0.05).
Other variables included in univariable Cox regression were: age,
gender, treatment, adjuvant treatment, and radiation dose. None
of these variables was a signiﬁcant predictor of DFS (P>0.05). Both
signiﬁcant variables remained signiﬁcant when adding both pri-
mary tumor volume on T1 (P=0.009) and ADC1000 of the lymph
node (P=0.014) to a multivariable Cox regression model (Table 4).
When including CE-T1WI in image analysis, high lymph node
ADC1000 (P<0.001) was also a signiﬁcant predictor of DFS in
univariable Cox regression. In a multivariable Cox regression
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model both primary tumor volume on T1 (P=0.011) and lymph
node ADC1000 (P=0.002) remained signiﬁcant predictors (Table 4).
Kaplan–Meier curves of the signiﬁcant predictors are shown in
Fig. 3.
4. Discussion
To our knowledge this is the ﬁrst study that assesses the pre-
dictive value of DWI without and with including CE-T1WI in image
analysis of HNSCC. Hatakenaka et al. [10] suggested that pretreat-
ment ADC would be superior to CE-MRI to predict local failure. We
did not ﬁnd any signiﬁcant differences in the predictive value of
DWI with or without including CE-T1WI in image analysis. The
intersession agreement was high (ICC=0.84–0.89). Differences in
ADC-values might be explained by a systematic error due to larger
ROI volumewhen includingCE-T1WI in image analysis. Thismaybe
causedbyperitumoral contrast-enhancement. In both settingshigh
lymphnodeADC1000 andprimary tumor volumewere independent
signiﬁcant predictors of DFS. These ﬁndings suggest that DWI anal-
ysis without CE-T1WI is non-inferior to DWI including CE-T1WI
in image analysis for predicting DFSDFS. The inclusion of CE-T1WI
did not result in signiﬁcant improvements in the predictive value
of DWI. This suggests that DWI can be used to detect necrosis at a
comparable level as CE-T1WI, or at least without clinically signiﬁ-
cant differences. An advantage of DWI compared to CE-T1WI is that
it can be used in patients with renal failure.
In our study high pretreatment lymph node ADC1000 was a sig-
niﬁcant predictor of treatment response. Kim et al. [12] also found
high pretreatment ADC of metastatic lymph nodes in HNSCC to be
a signiﬁcant predictor of local failure in a study on 33 patients with
a median follow-up of 12 months. Sensitivity and speciﬁcity were
65% and 86%, respectively.When the change in ADC-value between
pre-treatment DWI and DWI one week after the start of treatment
was used, sensitivity increased to 86% and speciﬁcity was 83%.
However, in a study on 37 HNSCC patients with a follow-up
of at least 2 years performed by King et al. [20], pretreatment
ADC was not a signiﬁcant predictor of local failure. Only ADC
changes between DWI examinations before and during treatment
showed a signiﬁcant correlation with treatment outcome. A (large)
increase of ADC-values in early follow-up was predictive of local
control. Treatment induced cell death may lead to reduced diffu-
sion restriction and therefore a rise in ADC-values. These ﬁndings
suggest that DWI before and during treatment (e.g. two weeks
after the start of (C)RT) provides the highest diagnostic accuracy
in response prediction. However, this is not yet implemented in
clinical practice because early follow-up MRI ﬁndings are not yet
incorporated in treatment protocols. Besides there is a logistic chal-
lenge, because for reliable repeated ADC measurements patients
need tobescannedon thesamescanner in thesamehospital, ideally
in the same position [21].
Malignant tissue is characterized by low ADC value implying
high cellularity compared to benign tissue [22]. In order to treat
HNSCC with (chemo)radiotherapy high cell turnover (i.e. low ADC)
is required as (chemo)radiotherapy mainly targets dividing cells
[23,24]. Therefore relatively high pre-treatment ADC may result in
adverse prognosis for patients treated with (chemo)radiotherapy
[12]. For surgery the relation between ADC and prognosis may be
different as more slowly dividing malignancies may be more easy
to remove radically, however this is beyond the scope of this article.
It should be noted that abscesses are also characterized by high
signal intensity on high b-value imaging combined with a low ADC
value and may therefore be difﬁcult to distinguish from malig-
nant tissue. In a study of Koc¸ et al. [25] on patients with necrotic
and cystic head and neck lesions abscesses could be differenti-
ated from (necrotic) tumors with a sensitivity and speciﬁcity of
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Fig. 1. MR images in a 59-year old male patient with a T3N2c oropharyngeal carcinoma (*). Necrosis (arrow) in the level II lymph node (arrowhead) is detected on (a) STIR
(hyperintensity), on (b) T1 minimal hypo-intensity is seen in the necrotic area. The ﬁndings of (c) b750 (high signal) and (d) ADC750 (high signal) are also indicative of necrosis.
On (e) CE-T1WI necrosis is seen due to low contrast-enhancement in the necrotic part of the lymph node (arrow). After 16 months of follow-up this patient remained disease
free.
Table 2
Agreement between ADC-values without and with including CE-T1WI in image analysis.
Variable Bias (10−3 mm2/s) LoA (10−3 mm2/s) ICC (95%CI)
Primary tumor ADC750 −0.18 −0.54; 0.18 0.84 (0.74–0.90)
Primary tumor ADC1000 −0.14 −0.42; 0.13 0.88 (0.80–0.92)
Lymph node ADC750 −0.15 −0.42; 0.14 0.89 (0.81–0.94)
A
T
R
ALymph node ADC1000 −0.15
bbreviations: ADC, Apparent diffusion coefﬁcient; ICC, Intraclass correlation coefﬁcient;
able 3
esults of ROC-analysis. The highest YI was used to determine the optimal cut-off value.
Parameters Cut-off
Tumor volume on T1 7.3 cm3
Lymph node volume on T1 0.8 cm3
Minimal axial diameter 7.6mm
Without CE-T1WI
Primary tumor ADC750 1.63×10−3 mm2/s
Primary tumor ADC1000 1.73×10−3 mm2/s
Lymph node ADC750 1.63×10−3 mm2/s
Lymph node ADC1000 1.51×10−3 mm2/s
With CE-T1WI
Primary tumor ADC750 1.55×10−3 mm2/s
Primary tumor ADC1000 1.44×10−3 mm2/s
Lymph node ADC750 1.83×10−3 mm2/s
Lymph node ADC1000 1.68×10−3 mm2/s
bbreviations: ADC, apparent diffusion coefﬁcient; AUC, area under the curve; CE-T1WI c−0.43; 0.12 0.85 (0.75–0.91)
LoA, Limits of agreement.
Sensitivity (%) Speciﬁcity (%) AUC
73 57 0.66
81 40 0.56
75 54 0.58
73 53 0.59
39 88 0.59
78 60 0.66
71 74 0.75
100 22 0.55
85 33 0.54
78 63 0.62
79 77 0.82
ontrast-enhanced T1-weighted imaging.
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igher ADC-value without including CE-T1WI in image analysis. (a) Primary tumor
00%. Abscesseswere characterized by even lower ADC values than
alignancies. The lower ADC value of abscesses is attributed to
he higher cell density in an abscess combined with the presence
f proteins and other macromolecules in abscesses [26]. Therefore
esions with high intensity on high b-value imaging and low ADC
alues cannot always considered to be malignant. Other sequences
nd clinical parameters (e.g. fever and tender lymphadenopathy)
ay further aid in differentiating abscesses from malignancy.
We used two sets of two b-values (0–750 s/mm2 and
–1000 s/mm2). In most clinical studies a maximum b-value of
000 s/mm2 is used [9–15]. Only King et al. [20] used a maximum
-value of 500 s/mm2 to limit signal loss and image distortion.
e used a TSE sequence for DWI instead of the more commonly
sed echo planar imaging (EPI) sequence. TSE sequences suffer
ess from geometric distortion, susceptibility artifacts and motion
rtifacts, but the signal-to-noise-ratio is lower [27]. Therefore the
se of a maximum b-value of 1000 s/mm2 could result in a too
ow signal-to-noise ratio to allow for proper image interpretation.
his is supported by our data; the image quality of b750-images
as rated slightly higher than b1000-images. Further the primary
umor and lymph node were more frequently visualized on b750-
mages (88% and96%, respectively) than onb1000-images (79% and
3%, respectively).ithout and with including CE-T1WI in image analysis. Positive values indicate a
0, (b) primary tumor ADC1000, (c) lymph node ADC750, (d) lymph node ADC1000.
In both primary tumor and lymph node ADC750 was higher
than ADC1000. This may be explained our assumption of a mono-
exponential model. In this model ADC values are lower at higher
b-values due to perfusion effects at low b-values due to a non-
linear relation between b-values and signal intensity. At higher
b-values a linear relation exists between b-value and signal
intensity. ADC values may be better represented with a biex-
ponential model which accounts for the perfusion effects at
low b-values [28]. It has also been shown that the high b-
value component (i.e. an ADC value obtained exclusively from
b-values above 500 s/mm2) has a stronger correlation with out-
come [29].
Verhappen et al. [30] compared primary tumor and lymph node
delineation between TSE-DWI and EPI-DWI in twelve patientswith
HNSCC. They concluded that lesions, in particular small lymph
nodes, are more easily visualized with EPI-DWI. This may be
explained by a lower signal-to-noise ratio of TSE-DWI compared to
EPI-DWI when using a maximum b-value of 1000 s/mm2. However
the results of TSE-DWI were more reproducible between observers
(ICC=0.79 for EPI-DWI vs ICC=0.92 for TSE-DWI). In our study ICC
was 0.92 in the primary tumor when only DWI is used. According
to the criteria of Nunnally [19] TSE-DWI would be clinically useful
only for primary tumor assessment.
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Fig. 3. Kaplan–Meier curves of (A) tumor volume on T1, (B) lymph node ADC1000 without including CE-T1WI in image analysis and (C) lymph node ADC1000 with including
C
S
n
i
m
A
d
a
wE-T1WI in image analysis.
In this manuscript we have used mean ADC values per ROI.
tandard deviations were also acquired, however these values did
ot show any signiﬁcant relations and were therefore not included
n the manuscript. Histogram analysis of ADC has been used as
arker of tumor heterogeneity (e.g. skewness, kurtosis, ADCmin or
DCmax) with promising results [31].This study had some limitations. In the ﬁrst place, all events in
isease-free survival analysis were considered equal, however not
ll events had the same clinical consequences. We did this because
e expect recurrent and residual disease to occur more frequentlyin the higher tumor stages, regardless of the severity of the event.
We also did not assess overall survival, because patients are some-
times referred to other institutions for palliative care. We therefore
could not reliably determine the time and cause of death. Secondly,
since patients were treated non-surgically it is not fully clear if
the largest lymph nodes really contained metastatic tissue. In our
institution ultrasound-guided ﬁne-needle aspiration cytology per-
formed by experienced investigators is used for N-staging, which
confers the risk of sampling errors. In reviews by de Bree et al. [32]
and de Bondt et al. [33] ultrasound guided ﬁne needle aspiration
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Table 4
Results of univariable and multivariable Cox regression without and including CE-
T1WI in image analysiswith theuseof CE-T1WI. Signiﬁcant predictors inunivariable
Cox regression were tested further with multivariable Cox regression analysis.
Parameter Univariable
Cox
regression, P
value
Multivariable
Cox
regression, P
value
Without CE-T1WI
Primary tumor volume on T1 (cm3) 0.001 0.009
Primary tumor ADC750 (10−3 mm2/s) 0.571 –
Primary tumor ADC1000 (10−3 mm2/s) 0.226 –
Lymph node volume on T1 0.763
Minimal axial lymph node diameter on T1 0.414
Lymph node ADC750 (10−3 mm2/s) 0.202 –
Lymph node ADC1000 (10−3 mm2/s) 0.001 0.014
With CE-T1WI
Primary tumor volume on T1 (cm3) 0.001 0.011
Primary tumor ADC750 (10−3 mm2/s) 0.572 –
Primary tumor ADC1000 (10−3 mm2/s) 0.471 –
Lymph node volume on T1 0.763
Minimal axial lymph node diameter on T1 0.414
Lymph node ADC750 (10−3 mm2/s) 0.240 –
Lymph node ADC1000 (10−3 mm2/s) <0.001 0.002
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[bbreviations: ADC, apparent diffusion coefﬁcient; CE-T1WI, contrast-enhanced T1-
eighted imaging.
ytology appears to be the best minimally invasive alternative to
he gold standard (i.e. histological examination after an elective
eck dissection).
Thirdly, 14 patients were excluded because neither tumor nor
ymphnodewas visible at both b-values. These patientsmainly had
mall lesions. Observers only had access to global tumor location,
ut not to the exact tumor location, the outcomeof other diagnostic
rocedures nor patient symptoms, which makes it more difﬁcult to
dentify small lesions.
. Conclusions
In conclusion, pretreatment primary tumor volume and the
ymph node ADC1000 are independent signiﬁcant predictors of DFS
n patientswithHNSCC treatedwith (C)RT. In addition, lymph node
DC1000 is a signiﬁcant predictor with and without including CE-
1WI in image analysis. DWI-analysis without CE-T1WI is highly
eproducible, demonstrated by good interobserver agreement.
DC-values were lower without than with including CE-T1W1
n image analsysis. The inclusion of CE-T1WI results in a lower
nterobserver agreement inmeasuring ADC onDWI. Therefore pre-
reatment DWI may be an additional tool to determine patient
rognosis. As injection of any contrast agents is not necessary to
erform DWI, using DWI without CE-T1WI may result in lower
maging costs with an equal predictive value. Further research is
ecessary to validate the value of TSE-DWI in response prediction
n comparison to EPI-DWI.
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